Clinical Trials
6 trialsNCT05588648 2025-04-10
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
MedPacto, Inc.
Phase 1/2 Recruiting
NCT03724851 2025-03-25
Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer
MedPacto, Inc.
Phase 1/2 Completed
NCT03698825 2024-12-09
TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer
MedPacto, Inc.
Phase 1/2 Completed
NCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
NCT06219733 2024-12-09
MP-VAC-206
MedPacto, Inc.
Phase 2 Withdrawn
NCT02160106 2019-05-09
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors
MedPacto, Inc.
Phase 1 Completed